Cochrane · systematic review · CD003463
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
Villar, JC, Perez, JG, Cortes, OL, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 28.6%Low 2 · 28.6%Moderate 2 · 28.6%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Nitroderivatives for chronic asymptomatic Trypanosoma cruzi infection
Population: people with chronic asymptomatic Trypanosoma cruzi infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Positive serology: RCT data ‐ nitroderivatives Conventional serology, AT and F29 ELISA techniques | OR 0.12 [0.03, 0.42] | 3 studies · 524 participants | Moderate |
Positive PCR: RCT data ‐ benznidazole‐ Children PCR | OR 0.51 [0.25, 1.04] | 1 study · 129 participants | Moderate |
Positive xenodiagnosis: all populations ‐ RCT data ‐ nitroderivatives Xenodiagnosis | OR 0.09 [0.04, 0.18] | 2 studies · 366 participants | High |
Mean reduction of antibodies titres: all populations, all tested drugs Mean change of antibodies | no estimate extracted | 3 studies · 225 participants | Low |
Nitroderivatives for chronic asymptomatic Trypanosoma cruzi infection
Population: people with chronic asymptomatic Trypanosoma cruzi infection
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
ECG Abnormalities ‐ RCT data ‐ benznidazole | OR 0.41 [0.07, 2.31] | 2 studies · 235 participants | Low |
Progression of cardiomyopathy: non‐RCT data ‐ adults ‐ nitroderivatives Emergence of substantial changes in the diagnostic tests or clinical status, or both (see text) | OR 0.74 [0.32, 1.73] | 4 studies · 986 participants | Very low |
Mortality: non‐RCT data ‐ adults ‐ nitroderivatives All‐cause mortality | OR 0.55 [0.26, 1.14] | 6 studies · 3396 participants | Very low |